A school project prompted 17-year-old Edward Kang to develop an AI tool that may lead to earlier diagnoses of the disorders.

This article explores how advances in AI, structural biology, and new drug modalities are transforming “undruggable” proteins ...

A novel PET imaging approach enables simultaneous visualization of tumor progression and cardiac inflammatory responses ...

Marking a significant advancement in transplant care in western Pennsylvania, a surgical team at AHN Allegheny General Hospital recently completed the region's first robotic-assisted kidney transplant ...

A recent study has identified a specific neural activity pattern as a novel biomarker to accurately predict and monitor the clinical status of individuals with obsessive-compulsive disorder (OCD) who ...

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-driven precision oncology company, today announced the launch of ...

“It's alarming how bad the situation is,” says Ambar Kulshreshtha a family medicine physician at Emory University in Atlanta, Georgia. He is referring to the ever-growing rate of Alzheimer’s disease ...

“Working with microRNAs is much more challenging than I expected,” says Fatima Heinicke, a molecular biologist in the Department of Medical Genetics at the University of Oslo. Her PhD research focused ...

Lantern Pharma Inc. , a clinical-stage, AI-driven precision oncology company, today announced the launch of ZetaOmics, the computational-biology module of its multi-agentic AI co-scientist platform, ...

The CRL indicates FDA deficiencies requiring added clinical evidence and CMC/product documentation, delaying potential availability of a nongadolinium liver MRI contrast option for advanced CKD ...